58 related articles for article (PubMed ID: 15254050)
1. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials.
Mourad N; Mounier N; Brière J; Raffoux E; Delmer A; Feller A; Meijer CJ; Emile JF; Bouabdallah R; Bosly A; Diebold J; Haioun C; Coiffier B; Gisselbrecht C; Gaulard P;
Blood; 2008 May; 111(9):4463-70. PubMed ID: 18292286
[TBL] [Abstract][Full Text] [Related]
2. The Prognosis of Adult Burkitt's Cell Leukemia in Real-Life Clinical Practice.
Malkan ÜY; Güneş G; Göker H; Haznedaroğlu İC; Acar K; Eliaçık E; Etgül S; Aslan T; Balaban S; Demiroğlu H; Özcebe OI; Sayınalp N; Aksu S; Büyükaşık Y
Turk J Haematol; 2016 Dec; 33(4):281-285. PubMed ID: 27094615
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of adults with lymphoma treated with nonmyeloablative TLI-ATG and radiation boost to high risk or residual disease before allogeneic hematopoietic cell transplant.
Dworkin ML; Jiang AL; Von Eyben R; Spinner MA; Advani RH; Lowsky R; Hiniker SM; Hoppe RT
Bone Marrow Transplant; 2022 Jan; 57(1):106-112. PubMed ID: 34671121
[TBL] [Abstract][Full Text] [Related]
4. What's new in peripheral T-cell lymphomas.
Luminari S; Skrypets T
Hematol Oncol; 2021 Jun; 39 Suppl 1(Suppl 1):52-60. PubMed ID: 34105820
[TBL] [Abstract][Full Text] [Related]
5. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.
Park SI; Horwitz SM; Foss FM; Pinter-Brown LC; Carson KR; Rosen ST; Pro B; Hsi ED; Federico M; Gisselbrecht C; Schwartz M; Bellm LA; Acosta M; Advani RH; Feldman T; Lechowicz MJ; Smith SM; Lansigan F; Tulpule A; Craig MD; Greer JP; Kahl BS; Leach JW; Morganstein N; Casulo C; Shustov AR;
Cancer; 2019 May; 125(9):1507-1517. PubMed ID: 30694529
[TBL] [Abstract][Full Text] [Related]
6. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.
O'Connor OA; Horwitz S; Masszi T; Van Hoof A; Brown P; Doorduijn J; Hess G; Jurczak W; Knoblauch P; Chawla S; Bhat G; Choi MR; Walewski J; Savage K; Foss F; Allen LF; Shustov A
J Clin Oncol; 2015 Aug; 33(23):2492-9. PubMed ID: 26101246
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorders.
Cai Q; Chen K; Young KH
Exp Mol Med; 2015 Jan; 47(1):e133. PubMed ID: 25613730
[TBL] [Abstract][Full Text] [Related]
8. Treatment of peripheral T cell lymphoma with an intensive protocol ACEP (adriamycin, cyclophosphamide, etoposide and prednisolone) and ifosfamide showing an important response and overall survival rates.
Salamoon M; Bachour M; Hussein T; Kenj M
Med Oncol; 2013 Jun; 30(2):554. PubMed ID: 23550277
[TBL] [Abstract][Full Text] [Related]
9. Impact of autologous and allogeneic stem cell transplantation in peripheral T-cell lymphomas.
Reimer P
Adv Hematol; 2010; 2010():320624. PubMed ID: 21253465
[TBL] [Abstract][Full Text] [Related]
10. Hemopoietic stem cell transplantation in T-cell malignancies: who, when, and how?
d'Amore F; Jantunen E; Relander T
Curr Hematol Malig Rep; 2009 Oct; 4(4):236-44. PubMed ID: 20425413
[TBL] [Abstract][Full Text] [Related]
11. High dose chemotherapy and autologous stem cell transplantation in non-Hodgkin's lymphoma: an eight-year experience.
Chang H; Cheong JW; Hahn JS
Yonsei Med J; 2006 Oct; 47(5):604-13. PubMed ID: 17066504
[TBL] [Abstract][Full Text] [Related]
12. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF;
J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases].
Yao B; Li YX; Fang H; Jin J; Liu XF; Yu ZH
Ai Zheng; 2006 Apr; 25(4):465-70. PubMed ID: 16613682
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy of the CHVmP/BV regimen used for aggressive non-Hodgkin's lymphoma in three randomised EORTC trials.
Moser EC; Noordijk EM; van Glabbeke M; Teodorovic I; de Wolf-Peeters C; Carde P; Baars JW; Tirelli U; Raemaekers JM; Kluin-Nelemans JC
Eur J Cancer; 2004 Mar; 40(4):474-80. PubMed ID: 14962711
[TBL] [Abstract][Full Text] [Related]
15. Anaplastic large cell lymphoma, ALK-positive.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2012 Aug; 83(2):293-302. PubMed ID: 22440390
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte.
Mounier N; Gisselbrecht C; Brière J; Haioun C; Feugier P; Offner F; Recher C; Stamatoullas A; Morschhauser F; Macro M; Thieblemont C; Sonet A; Fabiani B; Reyes F;
J Clin Oncol; 2004 Jul; 22(14):2826-34. PubMed ID: 15254050
[TBL] [Abstract][Full Text] [Related]
17. Autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas in first complete or partial remission: a retrospective analysis of the outcome of 52 patients according to the age-adjusted International Prognostic Index.
Fanin R; Silvestri F; Geromin A; Infanti L; Sperotto A; Cerno M; Stocchi R; Savignano C; Rinaldi C; Damiani D; Baccarani M
Bone Marrow Transplant; 1998 Feb; 21(3):263-71. PubMed ID: 9489649
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
